WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H558183
CAS#: 131916-69-3
Description: KB 5666 is a quinazoline derivative and lipid peroxidation inhibitor. Histologic, immunohistochemical and receptor-autoradiographic data indicate that KB-5666 protects the brain from both cellular and functional consequences of ischemia.
Hodoodo Cat#: H558183
Name: KB 5666
CAS#: 131916-69-3
Chemical Formula: C24H32N4O5
Exact Mass: 456.24
Molecular Weight: 456.540
Elemental Analysis: C, 63.14; H, 7.07; N, 12.27; O, 17.52
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: KB 5666; KB-5666; KB5666;
IUPAC/Chemical Name: Quinazoline, 4-(pentyloxy)-2-(4-(2-propenyl)-1-piperazinyl)-, (E)-2-butenedioate (1:1)
InChi Key: SGDNWFHKGDZSEZ-WLHGVMLRSA-N
InChi Code: InChI=1S/C20H28N4O.C4H4O4/c1-3-5-8-16-25-19-17-9-6-7-10-18(17)21-20(22-19)24-14-12-23(11-4-2)13-15-24;5-3(6)1-2-4(7)8/h4,6-7,9-10H,2-3,5,8,11-16H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
SMILES Code: C=CCN1CCN(C2=NC(OCCCCC)=C3C=CC=CC3=N2)CC1.O=C(O)/C=C/C(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 456.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Shimohara K, Niida H, Okabe S. Effects of KB-5492, 1-(3,4,5-trimethoxybenzyl)-4-((4-methoxyphenyl)oxycarbonylmethyl) p iperazine monofumarate monohydrate, on gastric lesions and gastric secretion in rats. Jpn J Pharmacol. 1990 Jun;53(2):275-9. PubMed PMID: 2385012.
2: Harada Y, Hara H, Sukamoto T. Binding properties of KB-5492, a novel anti-ulcer agent, at sigma receptors in porcine gastric fundic mucosa. Eur J Pharmacol. 1994 Aug 11;261(1-2):91-6. PubMed PMID: 8001658.
3: Harada Y, Hara H, Sukamoto T. Receptor binding profiles of KB-5492, a novel anti-ulcer agent, at sigma receptors in guinea-pig brain. Eur J Pharmacol. 1994 May 2;256(3):321-8. PubMed PMID: 8045277.
4: Morimoto Y, Shimohara K, Oshima S, Sukamoto T. Effects of the new anti-ulcer agent KB-5492 on experimental gastric mucosal lesions and gastric mucosal defensive factors, as compared to those of teprenone and cimetidine. Jpn J Pharmacol. 1991 Dec;57(4):495-505. PubMed PMID: 1803065.
5: Morimoto Y, Oshima S, Hara H, Sukamoto T. Effects of KB-5492, a new anti-ulcer agent, on ethanol- and acidified aspirin-induced gastric mucosal damage in vivo and in vitro. Jpn J Pharmacol. 1994 Jan;64(1):41-7. PubMed PMID: 8164392.
6: Morimoto Y, Shimohara K, Tanaka K, Hara H, Sukamoto T. 4-Methoxyphenyl 4-(3,4,5-trimethoxybenzyl)-1-piperazineacetate monofumarate monohydrate (KB-5492), a new anti-ulcer agent with a selective affinity for the sigma receptor, prevents cysteamine-induced duodenal ulcers in rats by a mechanism different from that of cimetidine. Jpn J Pharmacol. 1994 Mar;64(3):221-4. PubMed PMID: 8022123.
7: Hara H, Tanaka K, Harada Y, Sukamoto T. Sigma receptor-mediated effects of a new antiulcer agent, KB-5492, on experimental gastric mucosal lesions and gastric alkaline secretion in rats. J Pharmacol Exp Ther. 1994 May;269(2):799-805. PubMed PMID: 8182548.
8: Morimoto Y, Shimohara K, Oshima S, Hara H, Sukamoto T. Effects of KB-5492, a new anti-ulcer agent with a selective affinity for the sigma-receptor, on aspirin-induced disruption of the rat gastric mucosal barrier. Jpn J Pharmacol. 1994 Jan;64(1):49-55. PubMed PMID: 8164393.